On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The...more
Counterfeiting is seldom discussed in popular culture, but as a crime it is one of the most lucrative, eclipsing even the drug trade. In 2017, counterfeiting was responsible for almost $1 trillion in illegal sales....more
On May 8, 2020, the United States Patent and Trademark Office (USPTO) announced a COVID-19 Prioritized Examination Pilot Program, which will allow for prioritized examination of patent applications that contain at least one...more